Company Legal Name
Latest Valuation
Founded Year
Headquarter
Thirty Madison operates a specialized telehealth platform focused on treating chronic conditions including hair loss, migraines, acid reflux, and allergies. Founded in 2017 and headquartered in New York, the company differentiates itself by targeting specific chronic ailments rather than providing general telemedicine services. Through its digital-first approach, Thirty Madison connects patients with healthcare providers and delivers personalized treatment plans directly to consumers. The company has established multiple condition-specific brands within its platform ecosystem, enabling targeted marketing and specialized care pathways. Thirty Madison continues expanding its chronic condition portfolio while scaling its direct-to-consumer healthcare delivery model across the United States market.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





